Rapport Therapeutics, Inc. RAPP Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -28.3%— | —— | —— | —— | —— | |
| Return on assets | -26.8%— | —— | —— | —— | —— | |
| Return on invested capital | -38.2%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 27.1×-3.9× | 26.2×— | 36.4×— | 22.7×— | 31×— | |
| Quick ratio | 27.1×-3.9× | 26.2×— | 36.4×— | 22.7×— | 31×— | |
| Cash ratio | 4.4×-1.8× | 2.8×— | 17.6×— | 4.6×— | 6.1×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×— | 0×— | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×— | 0×— | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $9.98+23.2% | $12.45-15.5% | $13.49+45.5% | $7.43-76.5% | $8.11+142% | |
| Valuation | ||||||
| Market capitalization | $1.5B+309% | $1.45B— | $1.37B— | $451.84M— | $366.06M— | |
| Enterprise value | $1.43B+352% | $1.4B— | $1.13B— | $408.64M— | $316.3M— | |
| Price / book | 3.2×+1.9× | 3×— | 2.7×— | 1.7×— | 1.3×— | |
| Free cash flow yield | -5.4%+13.5pp | -6.1%— | -5.7%— | -17%— | -18.9%— | |
| Earnings yield | -7.2%+14.6pp | -7.7%— | -7.1%— | -19.5%— | -21.8%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Rapport Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.